U.S. Markets open in 5 mins.

Osiris Therapeutics, Inc. (OSIR)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
6.82-0.14 (-2.01%)
At close: 3:29PM EDT
People also watch
CYTXCURPSTIOPXAVNDA
  • Keep your arms inside the car ... preparing for blast off? $7 and new 52 week high coming up?
  • BIG bid at $6.90. A big player(s) wants in now and lowest ask is $7.05. Something just around the next bend?
  • Yahoo has New Venture up 2.49+0.26 (+11.66%)
    As of 4:25 AM EST.
  • “The most common procedures for cartilage restoration are:
    Microfracture Drilling, Biocartilage implantation (Arthrex), CARTIFORM (Arthrex), DeNovo NT (Zimmer), Autologous Chondrocyte Implantation (ACI)/Matrix Autologous Chondrocyte Implantation (MACI), Osteochondral Autograft Transplantation, Osteochondral Allograft Transplantation”

    http://www.activeorthopedic.com/specialties/cartilage-restoration/

    Cartilage Restoration Surgery Bergen County Essex County NJ Offices
    We’re pioneering surgical techniques that stimulate the growth of new cartilage to relieve pain. 4 convenient offices in Bergen and Essex County
    www.activeorthopedic.com
  • Maybe it takes a while to update but Scottrade shows a close of $6.82 and an ask of $6.80. Lots of games.
  • Well, pps is growing on the hope of good finance updates from CEO. And I hope that new CEO doesn't need 100 days to make some announcement about past and future of OSIR. And I hope that new paper about OSIR will not have a title like "Osiris Therapeutics names new CEO — again stupid one". Once again, several weeks of new CEO silence is OK, but several months of silence will be a sign of stupidity and ignorance. She must say something before 08/10/17 i.e. 1 months from start. OSIR gave her $450k salary and this is not for stupid several months silence.
  • $OSIR is searching for 2 Research Associate/Scientist, Process Development
    Job ID 2017-1207, a one up numbering system implies growth in headcount.

    The Process Development Scientist will be a part of a process development team responsible for development of manufacturing processes for the production of human cell and tissue products (HCT/Ps) compliant with current regulatory requirements, perform process optimization and troubleshooting, and technical transfer of developed processes for internal manufacturing and external manufacturing at contract manufacturing organizations (CMOs). The candidate will design experiments, workflows, collect, and record and interpret data appropriately. Data will be presented in internal and external meetings. The candidate will train other personnel on techniques and equipment. The process development scientist will report to the process development group leader.

    https://jobs-osiris.icims.com/jobs/1207/research-associate-scientist%2c-process-development/job

    Careers - Osiris Therapeutics, Inc.
    jobs-osiris.icims.com
  • Hit 7 at 15:30
  • New publication supports the science for Grafix

    Understanding the Impact of Preservation Methods on the Integrity and Functionality of Placental Allografts
    Annals of Plastic Surgery: August 2017 - Volume 79 - Issue 2 - p 203–213

    Results: The structure and thickness of fresh hPM were retained in vCHAM but were compromised in dHACM. Similar to fresh hPM, vCHAM contained viable cells, whereas dHACM did not. Cells in vCHAM remained viable after 4 and 7 days in culture and in an in vitro chronic wound environment and after 4 and 8 days in vivo after application to a mouse chronic wound. Staining for bromodeoxyuridine and Ki-67 did not reveal proliferative cells within fresh hPM and vCHAM. However, isolated cells proliferated in culture. Viable cryopreserved human amniotic membrane increased platelet-derived growth factor BB, hepatocyte growth factor, and epidermal growth factor levels over time and responded to chronic wound stimuli in vitro by significantly increasing levels of vascular endothelial growth factor and prostaglandin E2. Dehydrated human amnion/chorion membrane showed no significant accumulation of growth factors and did not respond to chronic wound stimuli.

    Conclusions: These results indicate that vCHAM retains intact, native matrix, and viable, active cells and responds to chronic wound stimuli in vitro. The inclusion of multiple layers of hPM does not compensate for structural degradation and loss of viability caused by dehydration as evidenced by a lack of functional response by dHACM. The clinical significance of these results remains to be answered.
  • It's 10:10 AM July 21, 2017, do you know where your financial statements are?
  • C'MON $7, then onward & upward. :-)
  • Babykahn and Techfan20

    I appreciate you sharing your information. Your post are most productive and informative . I reprint the 8k about Lode's resignation. Seems mutual, he got his options extended, and there is the standard noncompeting clause. Look forward to further info!
    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

    (e) Separation and Release Agreement with Lode Debrabandere, Ph.D.

    Osiris Therapeutics, Inc. (the “ Company ”) is filing this Current Report on Form 8-K/A to amend its Current Report on Form 8-K filed on February 3, 2016 (the “ Original Filing ”) that reported, among other things, the resignation of Lode Debrabandere, Ph.D., as the Company’s Chief Executive Officer, President, and a director. This Form 8-K/A amends and supplements the Original Filing to disclose the terms of Dr. Debrabandere’s resignation as required pursuant to Item 5.02 on Form 8-K.

    On February 22, 2016, the Company and Dr. Debrabandere entered into a Separation and Release Agreement (the “Agreement ”), that provides for, among other terms, (i) a separation date of February 16, 2016 (the “ Separation Date ”), (ii) a consulting period from the Separation Date through May 31, 2016 for Dr. Debrabandere to assist with the smooth and orderly transition of his former responsibilities, (iii) reimbursement for the extension of certain employee benefits during the consulting period if elected by Dr. Debrabandere, (iv) extension of the expiration date to December 31, 2017 for up to 36,250 previously granted and exercisable stock options at their existing exercise prices, (v) non-disparagement, (vi) compliance with certain post-employment restrictions in Dr. Debrabandere’s Employment Agreement, including with respect to confidentiality, inventions and patents, non-competition and non-solicitation, and (vii) a release of claims by Dr. Debrabandere.
  • 2017 Veteran Administration (VA) sales of Cartiform and BIO4:

    Cartiform Jan 2017 $43,472...BIO4 $8,218.
    Cartiform Feb 2017 $51,229...BIO4 $8,757.
    Cartiform Mar 2017 $96,896...BIO4 $4,725.
    Cartiform Apr 2017 $72,669...BIO4 $8,664.
    Cartiform May 2017 $17,000...BIO4 $0.
    Cartiform Jun 2017 $0.............BIO4 $91,598.
    Cartiform Jul 2017 $14,750...BIO4 $ 0.
    2017 Total Cartiform $296,016...BIO4 $121,362.
  • Osiris had $27M in cash and no debt as of Dec 31, 2016 per this filing
    http://investor.osiris.com/secfiling.cfm?filingID=1104659-17-19429&CIK=1360886

    and $10M was received last week from Mesoblast (see www.mesoblast.com, Under Latest News Click "10 July 2017 Cleansing notice and Appendix 3B >")

    and if 2017 operations are near breakeven,

    then there could be $1 per share in cash. and no debt.

    Not bad for a firm with $3.18 to $3.30 of revenue per share in 2016. ($110 to $114 )/34.5 million shares

    Osiris Therapeutics - Current Report
    investor.osiris.com
  • Aziyo Biologics, Inc

    check out the leadership page...

    Then check out the products page...

    Then check out the corporate headquarters location...
  • New Venturetec doesn't post much information either. Must be something with the management.
  • Osiris is searching for a Scientist - Process Development Lead

    PRIMARY PURPOSE OF THIS POSITION:
    Develop and optimize cell culture processes for the production of recombinant antibodies and other recombinant proteins.

    https://www.linkedin.com/jobs/view/369325990?trkInfo=searchKeywordString%3A%2CsearchLocationString%3A%252C%2B%2Cvertical%3Ajobs%2CpageNum%3A1%2Cposition%3A2%2CMSRPsearchId%3Accf11f00-ab1d-449b-9f9f-c1c52ac1f88b&refId=ccf11f00-ab1d-449b-9f9f-c1c52ac1f88b&trk=jobs_jserp_job_listing_text

    Scientist - Process Development Lead
    PRIMARY PURPOSE OF THIS POSITION: Develop and optimize cell culture processes for the production of recombinant antibodies and other recombinant proteins. RESPONSIBILITIES: The specific duties and responsibiliti
    www.linkedin.com
  • Osiris is searching for an Associate Regional Sales Specialist in the Raleigh-Durham, North Carolina Area

    https://www.linkedin.com/jobs/view/369353970?trkInfo=searchKeywordString%3A%2CsearchLocationString%3A%252C%2B%2Cvertical%3Ajobs%2CpageNum%3A1%2Cposition%3A1%2CMSRPsearchId%3Accf11f00-ab1d-449b-9f9f-c1c52ac1f88b&refId=ccf11f00-ab1d-449b-9f9f-c1c52ac1f88b&trk=jobs_jserp_job_listing_text

    Associate Regional Sales Specialist
    We are looking for a go getter, able to navigate the medical system and build relationships in order to heal patients. The Associate Sales Specialist is a field based position where the Specialist acts as an ambassador for Osiris Therapeutics
    www.linkedin.com
  • Mr. Market thinks the market for Osiris shares is terribly inefficient and they might best be traded at a flea market.
  • Next step, canceled contract with styker and artrex for bio4 and cartiform.
    Next step, sale of grafix and nothing comes to us.
    Next step, all our technology goes to aziyo.
    Final of the story: Peter takes the money, we stay with nothing in his hand, and ozark will say it's a good thing ....
    Ps: I stay longs I want to see how stupid I am